MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma

Phase 4
Completed
Conditions
Asthma
Interventions
First Posted Date
2020-02-19
Last Posted Date
2024-12-10
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
100
Registration Number
NCT04276233
Locations
🇮🇳

GSK Investigational Site, Pune, India

Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes

Phase 4
Withdrawn
Conditions
Asthma in Children
Dyspnea; Asthmatic
Obesity, Childhood
Interventions
Other: Control
Drug: Albuterol
First Posted Date
2019-12-03
Last Posted Date
2023-11-07
Lead Sponsor
Ohio State University
Registration Number
NCT04184609
Locations
🇺🇸

The Ohio State University, Columbus, Ohio, United States

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Phase 4
Completed
Conditions
Severe Eosinophilic Asthma
Asthma
Interventions
First Posted Date
2019-11-12
Last Posted Date
2025-01-09
Lead Sponsor
AstraZeneca
Target Recruit Count
170
Registration Number
NCT04159519
Locations
🇬🇧

Research Site, Nottingham, United Kingdom

Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia

Phase 4
Recruiting
Conditions
Hyperkalemia
Interventions
First Posted Date
2019-07-09
Last Posted Date
2024-04-30
Lead Sponsor
Nantes University Hospital
Target Recruit Count
525
Registration Number
NCT04012138
Locations
🇫🇷

Agen Hospital, Agen, France

🇫🇷

Angers University Hospital, Angers, France

🇫🇷

University Hospital, Clermont-Ferrand, Clermont-Ferrand, France

and more 13 locations

Physiological Response to Salbutamol and Exercise

Not Applicable
Conditions
Healthy
Interventions
Other: exercise
Drug: salbutamol
First Posted Date
2019-04-03
Last Posted Date
2020-11-03
Lead Sponsor
University of Copenhagen
Target Recruit Count
40
Registration Number
NCT03902106
Locations
🇩🇰

August Krogh Building, Copenhagen, Denmark

A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma

Phase 4
Completed
Conditions
Asthma
Interventions
First Posted Date
2019-03-26
Last Posted Date
2022-12-07
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
333
Registration Number
NCT03890666
Locations
🇺🇸

Teva Investigational Site 14197, Aventura, Florida, United States

🇺🇸

Teva Investigational Site 14302, Los Angeles, California, United States

🇺🇸

Teva Investigational Site 14195, Savannah, Georgia, United States

and more 27 locations

Salbutamol Administration by Nebulizer Versus Metered Dose Inhaler With Spacer in Asthma in Children

Phase 3
Completed
Conditions
Bronchial Asthma
Interventions
Device: Nebulizer
Drug: Salbutamol
Device: Metered dose inhaler and spacer
First Posted Date
2019-01-25
Last Posted Date
2019-04-04
Lead Sponsor
Suez Canal University
Target Recruit Count
60
Registration Number
NCT03816267
Locations
🇪🇬

Suez Canal University Hospital, Ismailia, Egypt

Nebulized Epinephrine vs. Salbutamol in Bronchiolitis Among Children

Not Applicable
Completed
Conditions
Respiratory Distress Score
Interventions
First Posted Date
2019-01-24
Last Posted Date
2022-08-30
Lead Sponsor
Makassed General Hospital
Target Recruit Count
90
Registration Number
NCT03814954
Locations
🇱🇧

Makassed General Hospital, Beirut, Lebanon

Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma

Active, not recruiting
Conditions
Asthma
First Posted Date
2018-07-19
Last Posted Date
2022-11-01
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
99
Registration Number
NCT03592212
Locations
🇫🇷

Hôpital Necker -Enfants Malades, Paris, France

A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2018-06-19
Last Posted Date
2022-10-21
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
300
Registration Number
NCT03562195
Locations
🇨🇳

GSK Investigational Site, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath